{
  "id": "5e4b5ef36d0a27794100001f",
  "type": "yesno",
  "question": "Does xaliproden improve prognosis of amyotrophic lateral sclerosis?",
  "ideal_answer": "No. There is not sufficient high quality evidence that xaliproden significantly improves prognosis of amyotrophic lateral sclerosis patients.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/22513921",
    "http://www.ncbi.nlm.nih.gov/pubmed/28072907",
    "http://www.ncbi.nlm.nih.gov/pubmed/15204012",
    "http://www.ncbi.nlm.nih.gov/pubmed/15204011"
  ],
  "snippets": [
    {
      "text": "Treatment for crampsThere is evidence (13 RCTs, N = 4012) that for the treatment of cramps in MND, compared to placebo:- memantine and tetrahydrocannabinol (THC) are probably ineffective (moderate-quality evidence);- vitamin E may have little or no effect (low-quality evidence); and- the effects of L-threonine, gabapentin, xaliproden, riluzole, and baclofen are uncertain as the evidence is either very low quality or the trial specified the outcome but did not report numerical data.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28072907",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The medications comprised vitamin E, baclofen, riluzole, L-threonine, xaliproden, indinavir, and memantine. Six studies assessed cramps as an adverse event. The medications comprised creatine, gabapentin, dextromethorphan, quinidine, and lithium. In all 20 studies no favourable effect for the treatment of cramps in ALS/MND could be demonstrated, but many studies were underpowered to draw a definite conclusion.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22513921",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": ". The six months intent-to-treat analysis showed no statistically significant effect but a trend in favour of 2 mg xaliproden compared to placebo for reduction in the rate of deterioration of FVC, limbs functional score, and manual muscle testing score (MMT).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/15204011",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "These results support the use of a staging process to select suitable patients for phase II studies, and suggest that xaliproden may have potential effects in ALS and deserve further study.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/15204011",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "An effect of xaliproden on functional parameters, especially VC, was noted. Although this effect did not reach statistical significance, xaliproden had a small effect on clinically noteworthy aspects of disease progression in ALS.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/15204012",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The six months intent-to-treat analysis showed no statistically significant effect but a trend in favour of 2 mg xaliproden compared to placebo for reduction in the rate of deterioration of FVC, limbs functional score, and manual muscle testing score (MMT).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/15204011",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "An effect of xaliproden on functional parameters, especially VC, was noted.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/15204012",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "These results support the use of a staging process to select suitable patients for phase II studies, and suggest that xaliproden may have potential effects in ALS and deserve further study.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/15204011",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The six months intent-to-treat analysis showed no statistically significant effect but a trend in favour of 2 mg xaliproden compared to placebo for reduction in the rate of deterioration of FVC, limbs functional score, and manual muscle testing score (MMT).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/15204011",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Although this effect did not reach statistical significance, xaliproden had a small effect on clinically noteworthy aspects of disease progression in ALS.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/15204012",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Yes"
}